Internal Reference Number: FOI_8205
Date Request Received: 15/10/2024 00:00:00
Date Request Replied To: 29/10/2024 00:00:00
This response was sent via: By Email
Request Summary: Request on lung cancer
Request Category: Researcher
| Question Number 1: How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: • ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib) • Amivantamab • Atezolizumab Monotherapy • Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel • Atezolizumab subcutaneous • Dabrafenib + Trametinib • Docetaxel monotherapy or in combination with Carboplatin/Cisplatin • Durvalumab • Gemcitabine • Nintedanib + Docetaxel • Nivolumab • Osimertinib • Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib) • Paclitaxel • Pembrolizumab Monotherapy • Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin) • Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin) • Pemetrexed + Platinum (Carboplatin/Cisplatin) • RET Inhibitors (Pralsetinib, Selpercatinib) • Sotorasib • Tepotinib • Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin • Other active systemic anti-cancer therapy • Palliative care only | |
| Answer To Question 1: • ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib) 6 • Amivantamab 0 • Atezolizumab Monotherapy 6 • Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel <5 • Atezolizumab subcutaneous <5 • Dabrafenib + Trametinib <5 • Docetaxel monotherapy or in combination with Carboplatin/Cisplatin 0 • Durvalumab <5 • Gemcitabine 0 • Nintedanib + Docetaxel <5 • Nivolumab 0 • Osimertinib 18 • Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib) <5 • Paclitaxel 0 • Pembrolizumab Monotherapy <5 • Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin) <5 • Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin) 12 • Pemetrexed + Platinum (Carboplatin/Cisplatin) <5 • RET Inhibitors (Pralsetinib, Selpercatinib) 0 • Sotorasib <5 • Tepotinib 0 • Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin <5 • Other active systemic anti-cancer therapy 0 • Palliative care only - 11 patients. | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of ¾¨Ó㴫ý Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
